Alpha Teknova (TKNO) Non-Current Deffered Revenue (2020 - 2021)
Alpha Teknova (TKNO) reported Non-Current Deffered Revenue of $269000.0 for Q4 2021, up 31.86% year-over-year from $204000.0 in Q4 2020, and up 1.89% quarter-over-quarter from $264000.0 in Q3 2021.
Alpha Teknova (TKNO) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Alpha Teknova (TKNO) has 2 years of Non-Current Deffered Revenue data on file, last reported at $269000.0 in Q4 2021.
- Non-Current Deffered Revenue for Q4 2021 came in at $269000.0, up 31.86% year-over-year; the trailing twelve-month figure through Dec 2021 was $269000.0 (up 31.86% YoY), and the FY2021 annual result was $269000.0, up 31.86% from the prior year.
- Non-Current Deffered Revenue climbed to $269000.0 in Q4 2021 per TKNO's latest filing, from $264000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $269000.0 in Q4 2021 and troughed at $204000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Alpha Teknova | 249.27 Mn | 231.49 Mn | 3.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 269,000.00 |
| Sep 30, 2021 | 264,000.00 |
| Jun 30, 2021 | 253,000.00 |
| Dec 31, 2020 | 204,000.00 |